Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $62.96 million versus the consensus estimate of $60.69 million.

GUIDANCE:

Acadia Pharma sees FY2019 revenue of $280-300 million, versus the consensus of $291.2 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.